The hardest part of a treatment plan often isn't the appointment itself, but the days that follow. Patients go home with a binder of instructions, a head full of fears, and no one to call at 2 a.m. when a side effect triggers panic. London-based Nayara is betting that an AI companion, tuned for specific clinical pathways like breast cancer, can be that lifeline.
The startup, which announced a £387,865 pre-seed round led by SFC Capital in November 2026, describes its product as “the Conversational & Emotional Layer for Patient-Healthcare Interaction” [Nayara.ai website, retrieved 2026]. It sells not to consumers, but to hospitals, health systems, and medical-technology companies. The wedge is operational: filling the support gap between clinical visits with an agent that answers routine questions, provides personalized guidance, and escalates concerning responses to human care teams [Tech.eu, November 2026].
The clinical wedge
Nayara’s approach is pathway-specific. Rather than a general health chatbot, it builds AI agents for defined clinical journeys: breast-cancer support, medication adherence, pre-operative preparation, and medical-device onboarding [PERPLEXITY SONAR PRO BRIEF, web-grounded]. The platform engages patients proactively, answers protocol-specific questions, and is designed to identify issues,clinical or emotional,that require a provider’s attention [UK Tech News, November 2026]. For clinical teams, the trade is automation for oversight: the AI handles repetitive check-ins and education, while surfacing risk flags and summarized patient updates for review.
Its most advanced agent to date is a breast-cancer companion, which the company reports has already supported hundreds of patients [Nstartup, November 2026]. The available coverage does not name the healthcare customer or provide independently verified clinical outcomes, a common pre-seed reality. The ambition, however, is clear. Co-founder Yael Kfir has stated the mission is to “disrupt cancer care with state-of-the-art LLM & AI agent cognitive architecture” [Yael Kfir - Peaks Life Science | LinkedIn, retrieved 2026].
The team and the traction signal
The founding team blends product and commercial experience, though their public biographies are lean on prior healthcare operator roles. Gal Moore, the CEO, was previously a product manager at robotics firm Cogniteam and a data scientist at ThetaRay [ContactOut, retrieved 2026]. Co-founder and Chief Commercial Officer Rami Kahan is described as a senior executive with strong sales experience in global tech companies [Rami Jonatan Kahan - Nayara.ai | LinkedIn, retrieved 2026]. The team’s composition suggests a bet that AI product execution and enterprise sales motion can be as critical as deep clinical domain expertise at this stage.
The recent pre-seed round, while modest, is a vote of confidence in that bet. SFC Capital’s lead suggests institutional investor interest in the ‘digital health layer’ thesis. The proceeds are earmarked for product development, clinical validation, and commercial expansion [StartupMag, November 2026].
| Role | Name | Notable Background |
|---|---|---|
| Co-founder & CEO | Gal Moore | Former Product Manager at Cogniteam; Data Scientist at ThetaRay [ContactOut, retrieved 2026] |
| Co-founder & CCO | Rami Kahan | Senior sales executive in global tech [Rami Jonatan Kahan - Nayara.ai |
| Co-founder | Eduard Rudyk | Not detailed in available sources |
| Co-founder | Yael Kfir | Peaks Life Science [Yael Kfir - Peaks Life Science |
| Head of Product | Guy Mizrachi | Not detailed in available sources |
Where the proof must come
For all its empathetic promise, Nayara operates in one of the most scrutinized arenas of applied AI. The path to scale is paved with regulatory, clinical, and commercial hurdles that its pre-seed funding only begins to address. The company’s next twelve months will be defined by its ability to convert early usage into validated evidence.
- Clinical validation. The strongest counter-bet is that healthcare providers will not trust an AI agent with patient guidance without rigorous, peer-reviewed evidence of safety and efficacy. A report of supporting “hundreds” of patients is a start, but it is not a published outcome study [Nstartup, November 2026]. Nayara must demonstrate its agents improve adherence, reduce anxiety, or cut down on unnecessary clinical contacts.
- Regulatory navigation. While the platform may be sold as a Software-as-a-Medical-Device (SaMD) or a clinical decision support tool, its classification with bodies like the UK’s MHRA or the FDA will shape its deployment and sales cycles. The company has not publicly detailed its regulatory strategy.
- Commercial motion. Selling into hospital IT departments or to medtech partners is a long, consensus-driven process. The team’s commercial experience will be tested against the notoriously slow procurement cycles of large health systems.
The opportunity Nayara is chasing is profound because the status quo is so inadequate. For a patient navigating a breast cancer diagnosis, the standard of care today is often a packet of papers and a phone number for a nurse's line that is busy. The emotional and logistical burden falls almost entirely on the individual and their family during the 99% of time they are not in a clinic. This is the population Nayara aims to serve: people in the vulnerable, confusing interval between appointments, who need accurate information and compassionate support on demand. If the AI companion works, it could become a quiet, essential layer in the architecture of chronic care, turning isolated patients into continuously supported participants in their own health. That is the humane bet at the heart of the code.
Sources
- [Tech.eu, November 2026] SFC Capital backs Nayara’s AI platform for patient care | https://tech.eu/2026/11/05/sfc-capital-backs-nayaras-ai-platform-for-patient-care/
- [Femtech World, November 2026] Nayara raises funding for AI breast cancer support | https://www.femtechworld.co.uk/news/cancer/nayara-raises-funding-for-ai-breast-cancer-support/
- [UK Tech News, November 2026] GY Health Technology (t/a Nayara) secures £387,865 Pre-Seed funding led by SFC Capital | https://www.uktechnews.info/2026/11/05/gy-health-technology-t-a-nayara-secures-387865-pre-seed-funding-led-by-sfc-capital/
- [StartupMag, November 2026] Nayara closes preseed round led by SFC Capital | https://www.startupmag.co.uk/funding/nayara-2026-pre-seed-funding/
- [Nstartup, November 2026] Nayara Raises Pre-Seed Funding Led by SFC Capital | https://nstartup.me/news/a2f4cc0e-4b46-4dc6-a3e2-986bb07e15e4
- [Nayara.ai website, retrieved 2026] Nayara, The Conversational & Emotional Layer for Patient-Healthcare Interaction | https://www.nayara.ai/
- [Yael Kfir - Peaks Life Science | LinkedIn, retrieved 2026] Yael Kfir - Peaks Life Science | LinkedIn
- [ContactOut, retrieved 2026] Gal Moore - Nayara.ai | ContactOut
- [Rami Jonatan Kahan - Nayara.ai | LinkedIn, retrieved 2026] Rami Jonatan Kahan - Nayara.ai | LinkedIn
- [PERPLEXITY SONAR PRO BRIEF, web-grounded] Nayara company and product description
- [Tali W. - Global Director, Operations | LinkedIn, retrieved 2026] Tali W. - Global Director, Operations | LinkedIn